Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Dec;47(1):2460726.
doi: 10.1080/0886022X.2025.2460726. Epub 2025 Feb 25.

Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia

Tian Xu  1 , Yilin Ruan  1 , Na Liu  2 , Yi Wang  2 , Xiujuan Zang  3 , Yuhua Ma  4 , Hualin Qi  5 , Xiuhua Mi  6 , Geping Yu  7 , Chunyan Zhang  1 , Xiaomin Huang  1 , Jingyuan Xie  1 , Nan Chen  1 , Hong Ren  1
Affiliations
Randomized Controlled Trial

Effect of roxadustat on lowering blood lipids in peritoneal dialysis patients with anemia

Tian Xu et al. Ren Fail. 2025 Dec.

Abstract

Objectives: To observe the effect of roxadustat on lowering blood lipids in peritoneal dialysis (PD) patients beyond treating anemia.

Methods: In a prospective, multicenter clinical study, we randomly assigned (in a 1:1 ratio) 100 PD patients who had received erythropoiesis-stimulating agent therapy for at least 4 weeks to receive either roxadustat or erythropoietin (EPO) for 48 weeks. The blood lipids, hemoglobin, blood pressure, blood glucose, iron metabolism and inflammatory factors were compared between the two groups at 0, 2, 4, 8, 12, 16, 20, 24 and 48 weeks, respectively.

Results: At start of switching to roxadustat, hemoglobin seemed to rise a little faster (102.8 ± 15.4 vs. 97.1 ± 17.3 g/L at 2 weeks, p > 0.05), but there was no significant difference in hemoglobin change between the two groups over the course of observation (p = 0.185). At the early stage of the study (12 weeks), the transferrin saturation (TSAT) of roxadustat group decreased significantly from the baseline (32.7 (20.6) vs. 22.1 (18.7)%, p = 0.001). At the end of the study period (48 weeks), total cholesterol (3.89 ± 0.92 vs. 4.52 ± 1.14 mmol/L, p = 0.012), low density lipoprotein cholesterol (2.24 ± 0.74 vs. 2.63 ± 0.82 mmol/L, p = 0.045) and triglyceride (1.35 (0.86) vs. 1.89 (1.27) mmol/l, p = 0.013) in roxadustat group were significantly lower than those in EPO group.

Conclusions: Roxadustat not only can improve anemia and iron metabolism, but also can reduce serum cholesterol and triglyceride levels in PD patients after switching from the EPO.

Keywords: Roxadustat; anemia; blood lipids; iron metabolism; peritoneal dialysis.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Study design.
Figure 2.
Figure 2.
Outcomes of enrolled patients.
Figure 3.
Figure 3.
Changes in hemoglobin.
Figure 4.
Figure 4.
Changes in blood pressure. SBP: Systolic blood pressure; DBP: Diastolic blood pressure.
Figure 5.
Figure 5.
Changes in glucose metabolism. FBG: Fasting blood glucose; Glycosylated Hb: Glycosylated hemoglobin
Figure 6.
Figure 6.
Changes in inflammatory factors. hs-CRP: Hypersensitive C-reactive protein; ESR: Erythrocyte sedimentation rate; IL-six: Interleukin-six.
Figure 7.
Figure 7.
Changes in iron metabolism. TSAT: Transferrin saturation.
Figure 8.
Figure 8.
Changes in total cholesterol.
Figure 9.
Figure 9.
Changes in LDL. LDL: Low density lipoprotein.
Figure 10.
Figure 10.
Changes in TG. TG: Triglyceride.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Kasiske BL. Hyperlipidemia in patients with chronic ­renal disease. Am J Kidney Dis. 1998;32(5 Suppl 3):S142–S156. doi: 10.1053/ajkd.1998.v32.pm9820472. - DOI - PubMed
    1. Jungers P, Massy ZA, Khoa TN, et al. . Incidence and risk factors of atherosclerotic cardiovascular accidents in predialysis chronic renal failure patients: a prospective study. Nephrol Dial Transplant. 1997;12(12):2597–2602. doi: 10.1093/ndt/12.12.2597. - DOI - PubMed
    1. Herzog CA, Asinger RW, Berger AK, et al. . Cardiovascular disease in chronic kidney disease. A clinical update from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2011;80(6):572–586. Cdoi: 10.1038/ki.2011.223. - DOI - PubMed
    1. Baigent C, Landray MJ, Reith C, et al. . The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377(9784):2181–2192. doi: 10.1016/S0140-6736(11)60739-3. - DOI - PMC - PubMed
    1. Wanner C, Krane V, März W, et al. . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353(3):238–248. doi: 10.1056/NEJMoa043545. - DOI - PubMed

Publication types

MeSH terms

LinkOut - more resources